Search results for "retreat"

showing 10 items of 90 documents

Historia Domu Rekolekcyjnego Konferencji Episkopatu Polski "Księżówka" w Zakopanem w latach 1945-1990

2017

Artykuł jest kontynuacją historii „Księżówki” - Domu Rekolekcyjnego Konferencji Episkopatu Polski w Zakopanem. Autor ukazuje w nim funkcjonowanie domu w peerelowskim okresie zmagań z władzami administracyjno-politycznymi o byt w warunkach narzucanych przez totalitarny ustrój.

Catholic Church in the Polish People’s RepublicZakopanedomy rekolekcyjne"Księżówka"Konferencja Episkopatu PolskiKościół w PRLretreat housePolish Bishops ConferenceStudia Teologiczno-Historyczne Śląska Opolskiego
researchProduct

Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C rea…

2019

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/13…

Resistance testmedicine.medical_specialtyHepatologybusiness.industryGastroenterologyDAA failurVironet C.NS5ARegimenInternal medicinemedicineretreatmentNS5AbusinessDigestive and Liver Disease
researchProduct

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

2016

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000 mg ofatumumab (Cycle 1; 300 mg) plus FC every 4 weeks for six cycles. Median C(max) and C(trough) values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher C(max) and C(trough) values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas …

OncologyMaleCancer ResearchLymphomaDrug ResistanceMedizinKaplan-Meier EstimatePharmacologychemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocols80 and overChronicNeoplasm MetastasisLenalidomideCancerAged 80 and overUnivariate analysisLeukemiaRemission InductionAntibodies MonoclonalHematologyphase IIMiddle AgedLymphocyticThalidomideFludarabineClinical trialTreatment OutcomeOncologyTolerability6.1 Pharmaceuticals030220 oncology & carcinogenesisRetreatmentMathematikRituximabFemalePatient SafetyRefractory Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic Leukemiamedicine.drugAdultmedicine.medical_specialtyCyclophosphamidelenalidomideClinical Trials and Supportive ActivitiesClinical SciencesImmunologyCmaxAntineoplastic AgentsNeutropeniaOfatumumabAntibodies Monoclonal HumanizedDrug Administration ScheduleArticle03 medical and health sciencesRare DiseasesClinical ResearchChemoimmunotherapyInternal medicinemedicineImmunologic FactorsAnimalsHumansIn patientAdverse effectLenalidomideAgedNeoplasm StagingChromosome Aberrationsbusiness.industryB-CellEvaluation of treatments and therapeutic interventionsmedicine.diseaseHaresLeukemia Lymphocytic Chronic B-CellDiscontinuationClinical trialchemistryDrug Resistance NeoplasmNeoplasmbusinessCLL030215 immunology
researchProduct

Combustion properties of spruce black liquor droplets : Sulfur-free pulping and influence of hot-water pretreatment

2016

Hot-water pretreatment of lignocellulosics prior to sulfur-free alkaline pulping is an interesting approach for recovering value-added carbohydrate- and lignin-derived materials. This paper investigated the chemical composition variations and combustion properties of the black liquors (BLs) from three different cooking processes: two sulfur-free soda-anthraquinone (soda-AQ) and oxygen-alkali (O2-NaOH) cooks and kraft cook, before and after hot-water pretreatment of the spruce sawdust. Relatively less aliphatic acids but more lignin were present in the BLs after hot-water pretreatment as cooking time prolonged. In general, the burning time decreased as follows: soda-AQ BL > O2-NaOH BL ≅ kraf…

Waste management020209 energycombustion propertieshot-water pretreatmenteducationtechnology industry and agriculturesulfur-free pulpingchemistry.chemical_elementfood and beveragesForestrymustalipeä02 engineering and technologyCombustionPulp and paper industrySulfurchemistryhemic and lymphatic diseaseskuuset0202 electrical engineering electronic engineering information engineeringEnvironmental scienceGeneral Materials ScienceBlack liquor
researchProduct

The Effect of Mechanocatalytic Pretreatment on the Structure and Depolymerization of Willow

2020

In this study, the effect of a mechanocatalytic pretreatment on the structure of willow and sugar release from pretreated willow was explored. In the mechanocatalytic approach, the pretreatment consists of solvent-free impregnation with sulfuric acid and a mechanical treatment with ball milling. Willow sawdust and pretreated samples were analyzed with field emission scanning electron microscope and X-ray diffraction. The products in the sugar solution were determined as the total reducing sugars with the 3,5-dinitrosalicylic acid method and monosaccharides with capillary electrophoresis. According to the results, milling increased the sugar production, depending on the sulfuric acid load. T…

rikkihappo020209 energyselluloosaWillow sawdustpajut02 engineering and technology010501 environmental sciencesXyloseesikäsittelylcsh:Chemical technologycomplex mixtures01 natural sciencesCatalysisHydrolysatepolymerointilcsh:ChemistryBall millingchemistry.chemical_compoundlignocellulose0202 electrical engineering electronic engineering information engineeringmechanocatalytic pretreatmentMonosaccharidelcsh:TP1-1185Physical and Theoretical ChemistrySugarBall mill0105 earth and related environmental scienceschemistry.chemical_classificationDepolymerizationSulfuric acidsulfuric aciddigestive oral and skin physiologytechnology industry and agriculturefood and beveragesSulfuric acidwillow sawdustlcsh:QD1-999chemistryvisual_artvisual_art.visual_art_mediumball millingSawdustLignocelluloseMechanocatalytic pretreatmentNuclear chemistryCatalysts
researchProduct

Evaluation of three different rotary systems during endodontic retreatment - Analysis by scanning electron microscopy

2015

Background: Endodontic therapy is considered a series of important and interdependent steps, and failure of any of these steps may compromise the treatment outcome. This study aimed to evaluate the effectiveness of three different rotary systems in removing obturation materials during endodontic retreatment using scanning electron microscopy (SEM) analysis. Material and Methods: Thirty-six endodontically treated teeth were selected and divided into 3 groups of 10 and 1 control group with 6 dental elements. The groups were divided according to the rotary system used for removing gutta-percha, as follows: G1: ProTaper system; G2: K3 system; G3: Mtwo system; and G4: Control group. Thereafter, …

0301 basic medicineEndodontic therapyScanning electron microscopebusiness.industryResearchTreatment outcomeSignificant differenceObturation materialDentistryOdontología030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOperative Dentistry and Endodontics03 medical and health sciences030104 developmental biology0302 clinical medicineDentinal TubuleUNESCO::CIENCIAS MÉDICASMedicinebusinessGeneral DentistryEndodontic retreatmentJournal of Clinical and Experimental Dentistry
researchProduct

Selective Disintegration–Milling to Obtain Metal-Rich Particle Fractions from E-Waste

2022

This research was supported by ERDF project no. 1.1.1.1/20/A/139 “Development of sustainable recycling technology of electronic scrap for precious and non-ferrous metals extraction”. The project was co-financed by REACT-EU funding to mitigate the effects of the pandemic crisis. The article was published with the financial support from the Riga Technical University Research Support Fund. This research was also supported by the Institute of Solid State Physics, University of Latvia as the Center of Excellence has received funding from the European Union’s Horizon 2020 Framework Program H2020-WIDESPREAD-01-2016-2017-TeamingPhase2 under grant agreement No. 739508, project CAMART2. The authors w…

disintegratione-wasteMetals and Alloysprecious metalsprinted circuit boards:NATURAL SCIENCES::Physics [Research Subject Categories]e-waste millingGeneral Materials Sciencedisintegration; e-waste; e-waste mechanical pretreatment; e-waste milling; precious metals; printed circuit boardse-waste mechanical pretreatmentMetals
researchProduct

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterfe…

2013

GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a (40 kDa) plus ribavirin in previous nonresponders to peginterferon alpha-2b (12 kDa). BACKGROUND: In the randomized multinational retreatment with Pegasys in patients not responding to PegIntron therapy study, a 72-week regimen of peginterferon alpha-2a (40 kDa) plus ribavirin improved SVR rates over a standard 48-week regimen in previous nonresponders to peginterferon alpha-2b (12 kDa). cEVR, defined as hepatitis C virus RNA <50 IU/mL at treatment week 12, was an important predictor of SVR. STUDY: We conducted an exp…

AdultMalemedicine.medical_specialtyTime FactorsInterferon alpha-2Antiviral therapyAntiviral AgentsGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled trialnonresponderPredictive Value of TestslawInternal medicineRibavirinchronic hepatitis CHumansMedicinepeginterferonAdverse effectRandomized Controlled Trials as Topicbusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasepeginterferon; chronic hepatitis C; nonresponder; retreatment; sustained virological responseRecombinant Proteinsdigestive system diseasesRegimenTreatment OutcomechemistryPredictive value of testsRelative riskRetreatmentDrug Therapy CombinationFemalesustained virological responsebusinessJournal of Clinical Gastroenterology
researchProduct

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-[alpha]2b: A Randomized Trial

2009

BACKGROUND Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING 106 international centers. PATIENTS 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribav…

Malemedicine.medical_specialtyHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawPegylated interferonInternal medicineRibavirinInternal Medicineretreatment non responder hepatitis CHumansMedicineTreatment FailureNot evaluatedbusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesSurgerychemistryRetreatmentRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct